Medicines Co., Chiesi deal

Chiesi will purchase Medicines Co.’s non-core cardiovascular assets, including Cleviprex clevidipine, Kengreal cangrelor and the company’s rights to ready to use argatroban.

Read the full 222 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE